騰盛博藥-B(02137.HK):Brian Alvin Johns博士擔任公司首席科學官
格隆匯1月3日丨騰盛博藥-B(02137.HK)公吿,Brian Alvin Johns博士自2024年1月3日起擔任公司首席科學官。Johns博士將全面負責公司的新藥開發項目,並制定公司的未來管線策略和優先事項。
Johns博士在製藥行業擁有豐富的經驗,曾成功組建和領導多個團隊完成多個創新藥物的發現和早期開發項目。他對端到端研發目標的深刻理解在創造和提供差異化藥物方面發揮了關鍵作用,改變了許多患者的生活。
公司董事長兼首席執行官Zhi Hong博士表示:“我很高興能再次與Johns博士合作,由其擔任我們的首席科學官。他是業內新藥開發領域首屈一指的專家,他在大型製藥公司和初創生物技術公司工作的獨特經驗將為公司帶來助益”。
在加入公司之前,Johns博士曾在HemoShear Therapeutics, Inc.擔任首席科學官,負責帶領團隊開發各疾病領域的新靶點和平台。在此之前,他曾在ViiVHealthcare Limited(ViiV)和葛蘭素史克公司擔任新藥開發副總裁,為ViiV╱葛蘭素史克的HIV系列藥物做出了巨大貢獻,發現了多替拉韋和卡替拉韋這兩種突破性藥物。
Johns博士擁有化學博士學位,並因其在該領域的巨大貢獻獲得了眾多榮譽和獎項。他在藥物化學和藥物發現方面的豐富專業知識還體現在其獲得的眾多專利和發表的多個出版物中。
Johns博士表示:“我很高興能加入本公司,為感染性疾病的變革性療法開發貢獻力量。本公司專注於治癒性藥物和新型治療方案,並擁有一支備受認可的優秀團隊,我迫不及待地想成為該團隊的一員,與他們一起以突破性的創新和洞察,踐行解決重大公共衞生問題的使命”。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.